Healthcare / Medical DevicesTaipei Exchange
$73.90
+6.70 (+9.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $104.5M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.4B
P/E
16.3x
↓EV/EBITDA
10.1x
↓ROE
16.6%
↑Gross Margin
33.4%
↓Debt/Equity
0.69
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.3%
FCF CAGR
—
FCF margin
9.0%
FCF / Net income
0.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.11B · net income $208.6M · FCF $99.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.11B | $1.11B | $991.1M | $940.7M | $1.04B |
| Net Income | $208.6M | $208.6M | $170.2M | $152.3M | $153.8M |
| EBITDA | $393.2M | $393.2M | $329.6M | $303.0M | $306.6M |
| EPS | — | — | 4.08 | 3.71 | 4.34 |
| Gross Margin | 33.4% | 33.4% | 31.9% | 31.7% | 28.2% |
| Operating Margin | 23.5% | 23.5% | 21.6% | 21.0% | 18.7% |
| Net Margin | 18.8% | 18.8% | 17.2% | 16.2% | 14.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.69 | 0.69 | 0.88 | 0.74 | 1.09 |
| Current Ratio | 1.36 | 1.36 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $99.6M | $99.6M | $104.5M | $116.1M | $-381.4M |
| Returns | |||||
| ROE | 16.6% | 16.6% | 18.7% | 18.0% | 23.8% |
| Valuation | |||||
| P/E | 16.35 | 16.35 | 19.68 | 18.98 | — |
| EV/EBITDA | 10.14 | 10.14 | 12.05 | 11.41 | — |
| P/B | 2.67 | 2.67 | 3.69 | 3.46 | — |
| Growth & Yield | |||||
| Revenue Growth | 11.9% | 11.9% | 5.4% | -9.2% | — |
| EPS Growth | — | — | 10.0% | -14.5% | — |
| Dividend Yield | 5.5% | 5.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+32.7%
Start / end P/E
n/dx → n/dx
EPS bridge
4.08 → n/d
Residual
+27.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.